Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Double-blind, Randomised, Parallel Group Comparison of the Efficacy and Safety of FP-1201-lyo (Recombinant Human Interferon Beta-1a) and Placebo in the Treatment of Patients with Moderate or Severe Acute Respiratory Distress Syndrome

Next Previous
Trial Profile

A Phase III Double-blind, Randomised, Parallel Group Comparison of the Efficacy and Safety of FP-1201-lyo (Recombinant Human Interferon Beta-1a) and Placebo in the Treatment of Patients with Moderate or Severe Acute Respiratory Distress Syndrome

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 28 Mar 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Interferon beta-1a (Primary)
  • Indications Adult respiratory distress syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms INTEREST
  • Sponsors Faron Pharmaceuticals

Most Recent Events

  • 26 Mar 2022 This trial is completed in Belgium (End Date: 23 May 2018), according to European Clinical Trials Database record.
  • 20 May 2020 According to a Faron Pharmaceuticals media release, results of this study have been published in Intensive Care Medicine
  • 17 Feb 2020 Primary endpoint (Efficacy Endpoint: Days free of mechanical ventilation) has not been met published in the JAMA: the Journal of the American Medical Association

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top